JNJ USUSD232.77▲ +4.60 +2.02%
O --H 235.21L 229.00Prev 228.17Vol 5.6M52W 149.04 - 251.71Mkt $560.95BP/E 20.9NYSEPharmaceutical PreparationsCIK 0000200406
Price · 1Y
+50.1% 12M
AI Research Brief
fetching fundamentals & filings
Key Statistics
FY2025
Mkt cap
$560.95B
P/E
20.9
P/S
6.0
Rev growth
6.0%
Gross mgn
67.9%
Op margin
22.9%
Net margin
28.5%
ROE
32.9%
ROA
13.5%
Debt/Eq
0.48
Trailing Return
1W
+3.3%
1M
+3.6%
3M
-3.2%
6M
+13.4%
1Y
·
YTD
+12.3%
149.04
251.7152W
Financial History
value · YoY heat
| Metric | FY19 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | $82.06B | $82.58B | $78.74B | $85.16B | $88.82B | $94.19B |
| Gross profit | $54.50B | $54.16B | $55.34B | $58.61B | $61.35B | $63.94B |
| Operating income | · | · | · | · | · | · |
| Net income | $15.12B | $14.71B | $20.88B | $35.15B | $14.07B | $26.80B |
| Gross margin | 66.4% | 65.6% | 70.3% | 68.8% | 69.1% | 67.9% |
| Operating margin | · | · | · | · | · | · |
| Net margin | 18.4% | 17.8% | 26.5% | 41.3% | 15.8% | 28.5% |
Fundamentals
Dec 28, 2025
- Revenue
- $94.19B
- Gross profit
- $63.94B
- Operating income
- $21.59B
- Net income
- $26.80B
- Diluted EPS
- 11.03
- Total assets
- $199.21B
- Total liabilities
- $117.67B
- Shareholders' equity
- $81.54B
- Cash & equivalents
- $19.71B
- Long-term debt
- $39.44B
- Shares outstanding
- 2,409,898,936
Comparable Companies
Relative Valuation
reading the comps
Analyst Ratings
Ownership
Earnings Call
locating latest call
News
Catalysts & Events
Filings
Sources & As-Of
- SEC EDGAR — XBRL companyfactsDec 28, 2025
- SEC EDGAR — submissionsApr 28, 2026
- Yahoo Finance (price)Jun 5, 2026
Assembled Jun 8, 2026 · public data, may be delayed or incomplete · verify against primary filings · not advice